益肾抗瘤方联合IL-2腹腔灌注治疗卵巢癌相关腹水的疗效观察

doi:10.12092/j.issn.1009-2501.2018.12.016

中国临床药理学与治疗学 ›› 2018, Vol. 23 ›› Issue (12): 1408-1414.doi: 10.12092/j.issn.1009-2501.2018.12.016

益肾抗瘤方联合IL-2腹腔灌注治疗卵巢癌相关腹水的疗效观察

陈祥艳¹，陈聪²，孙云¹，张虹¹，高楚楚¹，陈舒¹

¹温州市中医院，温州 325000，浙江；²温州市人民医院，温州 325000，浙江

收稿日期:2018-08-13 修回日期:2018-11-08 出版日期:2018-12-26 发布日期:2018-12-27
通讯作者: 陈聪，女，硕士，副主任医师，研究方向：妇科盆底和肿瘤。 Tel: 13968850608 E-mail: shenjq88@163.com
作者简介:陈祥艳，女，硕士，主治中医师，研究方向：中医妇科。 Tel: 13868650226 E-mail: shenjq88@163.com
基金资助:
浙江省中医药科技计划项目（2015ZA199）

Effects of Yishen Kangliu recipe in combination with IL-2 peritoneal perfusion in treatment of ovarian cancer-associated ascites

CHEN Xiangyan¹, CHEN Cong², SUN Yun¹, ZHANG Hong¹, GAO Chuchu¹, CHEN Shu¹

¹ Wenzhou Hospital of Traditional Chinese Medicine, Wenzhou 325000, Zhejiang, China; ²Wenzhou People's Hospital, Wenzhou 325000, Zhejiang, China

Received:2018-08-13 Revised:2018-11-08 Online:2018-12-26 Published:2018-12-27

摘要/Abstract

摘要：

目的: 探讨益肾抗瘤方联合白细胞介素-2（IL-2）腹腔灌注治疗卵巢癌相关腹水的疗效。方法: 采用随机数字表法将98例卵巢癌相关腹水患者分为试验组49例与对照组49例，两组均给予紫杉醇联合卡铂化疗。在此基础上，对照组给予IL-2腹腔灌注治疗，试验组IL-2腹腔灌注联合益肾抗瘤方治疗。观察并比较两组患者的腹水控制有效率、癌胚抗原（CEA）、糖类抗原125（CA125）、人附睾蛋白4（HE4）、血管内皮生长因子（VEGF）、T淋巴细胞亚群变化、免疫球蛋白（Ig）A、IgM、IgG水平变化、不良反应及Karnofsky评分变化情况。比较两组的无进展生存期（PFS）。结果: 试验组腹水控制总有效率显著高于对照组（P＜0.05）。试验组的CA125总缓解率及控制率分别为71.4%、95.9%，均显著高于对照组的46.9%、83.7%（P＜0.05）。治疗后，试验组CEA、CA125、HE4及VEGF水平显著低于治疗前及对照组治疗后（P＜0.05）。试验组患者CD3+、CD4+、CD4+/CD8+、NK细胞及IgM、IgG水平显著高于治疗前和对照组（P＜0.05）。试验组胃肠道反应、白细胞下降、血小板降低、转氨酶升高、尿素氮升高及周围神经症状的发生率显著低于对照组（P＜0.05）。试验组的PFS为6.0（3~12）个月，显著长于对照组的4.0（2~10）个月（χ2=8.113，P<0.01）。结论: 益肾抗瘤方联合IL-2腹腔灌注治疗卵巢癌并发恶性腹水疗效确切，可有效抑制肿瘤细胞的增殖，改善患者生存质量，安全性较高，值得推广。

关键词: 益肾抗瘤方, 白细胞介素-2, 卵巢癌相关腹水, 免疫功能

Abstract:

AIM: To investigate the therapeutic effect of Yishen Kangliu recipe combined with IL-2 peritoneal perfusion on advanced ovarian cancer-related ascites. METHODS: Ninety-eight cases of ovarian cancer-related ascites were divided into experimental group (49 cases) and control group (49 cases) by random number table. Both groups were treated with paclitaxel combined with carboplatin. On the basis of this, the control group was given intraperitoneal infusion of IL-2, while the experimental group IL-2 intraperitoneal perfusion combined with Yishen Kangliu receipe treatment. The effective rate of ascites control, CEA, CA125, HE4, VEGF, T lymphocyte subsets, IgA, IgM, IgG level changes, adverse reactions and Karnofsky score changes, and PFS of the groups were compared. RESULTS: The total effective rate of the experimental group was significantly higher than that of the control group (P<0.05). The total remission rate and control rate of CA125 in the experimental group were 71.4% and 95.9% respectively, which were significantly higher than 46.9% and 83.7% in the control group (P<0.05). After treatment, the levels of CEA, CA125, HE4 and VEGF in the experimental group were significantly lower than those before treatment and after the control group (P<0.05). After treatment, the levels of CD3+, CD4+, CD4+/CD8+, NK cells and IgM, IgG in the experimental group were significantly higher than those before treatment, and the experimental group was significantly higher than the control group (P<0.05). Gastrointestinal reactions, leukopenia, thrombocytopenia, elevated transaminases, elevated urea nitrogen and peripheral neurological symptoms in the experimental group were significantly lower than those in the control group (P<0.05). PFS in the experimental group was 6.0 (3-12) months, which was significantly longer than that in the control group 4.0 (2-10) months (χ²=8.113, P<0.01). CONCLUSION: Yishen Kangliu recipe combined with IL-2 intraperitoneal perfusion in the treatment of ovarian cancer complicated with malignant ascites i can effectively inhibit the proliferation of tumor cells and improve the quality of life of patients with high safety.

Key words: Yishen Kangliu recipe, interleukin-2, ovarian cancer-related ascites, immune function

中图分类号:

陈祥艳，陈聪，孙云，张虹，高楚楚，陈舒. 益肾抗瘤方联合IL-2腹腔灌注治疗卵巢癌相关腹水的疗效观察[J]. 中国临床药理学与治疗学, 2018, 23(12): 1408-1414.

CHEN Xiangyan, CHEN Cong, SUN Yun, ZHANG Hong, GAO Chuchu, CHEN Shu. Effects of Yishen Kangliu recipe in combination with IL-2 peritoneal perfusion in treatment of ovarian cancer-associated ascites[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(12): 1408-1414.

[1]	李阳, 潘维忠, 张晓录, 于翠翠. 回收式自体血回输对行剖宫产术患者免疫功能及炎症反应的影响[J]. 中国临床药理学与治疗学, 2023, 28(5): 514-524.
[2]	谢方英，陈浙丽，高月蓝. 益气养阴生肌方对复发性口腔溃疡大鼠的治疗作用及其对黏膜炎症因子和机体免疫功能的影响[J]. 中国临床药理学与治疗学, 2019, 24(1): 20-26.
[3]	袁静，孙静雪，黄代强，袁琳，丁登峰. 小剂量右美托咪定联合乌司他丁对肺癌患者免疫功能和应激反应的影响[J]. 中国临床药理学与治疗学, 2019, 24(1): 83-88.
[4]	王婷，陈珂，周长平，王义桥，鲁显福，李元海. 精准麻醉对机器人辅助腹腔镜前列腺癌根治术患者围术期细胞免疫功能的影响[J]. 中国临床药理学与治疗学, 2018, 23(2): 175-179.
[5]	赵鹏程，张超. 七氟醚联合丙泊酚对肝硬化患者术后肝肾功能及免疫功能的影响[J]. 中国临床药理学与治疗学, 2018, 23(11): 1276-1281.
[6]	陈舟，黄和，陈其余. 参附注射液对乳腺癌术后化疗患者生存质量及其免疫功能的影响研究[J]. 中国临床药理学与治疗学, 2018, 23(10): 1159-1164.
[7]	罗勇，李崎，华特波. 新辅助化疗联合乳腺癌改良根治术对乳腺癌患者免疫功能、基质金属蛋白酶及血管内皮生长因子的影响[J]. 中国临床药理学与治疗学, 2018, 23(1): 104-109.
[8]	容国义，王淑美，唐末. 中医化痰法治疗非小细胞肺癌疗效的Meta分析[J]. 中国临床药理学与治疗学, 2017, 22(7): 787-794.
[9]	吴苗，刘永林，蔡云雅. 氟尿嘧啶外涂与干扰素注射联合液氮冷冻治疗多发性跖疣的疗效及对患者免疫功能的影响[J]. 中国临床药理学与治疗学, 2017, 22(3): 312-315.
[10]	罗玲玲，滕承志，李晓笑，潘丹峰. 阿奇霉素联合盐酸氨溴索治疗小儿支原体肺炎合并急性支气管炎的临床研究[J]. 中国临床药理学与治疗学, 2017, 22(11): 1278-1282.
[11]	俞良，邓芳，李庆华，丁卫华，李秀秀，孙建良. 经鞘内输注系统输注小剂量吗啡对顽固性晚期癌痛患者镇痛效果及细胞免疫功能的影响[J]. 中国临床药理学与治疗学, 2016, 21(8): 926-930.
[12]	杨小云，丁进，陈燕萍，沈敏瑾，王群英. 早期肠内营养支持对ICU脑卒中患者免疫功能及肠道黏膜屏障的影响[J]. 中国临床药理学与治疗学, 2016, 21(8): 935-938.
[13]	陈公锦, 欧阳葆怡. 布托啡诺对罗库溴铵作用时效的影响[J]. 中国临床药理学与治疗学, 2010, 15(3): 310-312.
[14]	代长青, 黄升海. 丙肝患者与合并HIV 感染者的免疫功能分析[J]. 中国临床药理学与治疗学, 2010, 15(3): 313-316.
[15]	刘琳娜, 郭志伟, 张琰, 覃华, 韩燕, 刘新友. 唐古特大黄多糖组分1对电离辐射损伤小鼠免疫功能的保护作用[J]. 中国临床药理学与治疗学, 2010, 15(11): 1201-1205.

益肾抗瘤方联合IL-2腹腔灌注治疗卵巢癌相关腹水的疗效观察

Effects of Yishen Kangliu recipe in combination with IL-2 peritoneal perfusion in treatment of ovarian cancer-associated ascites

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价